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Abstract	Subclavian vein stenosis is a common, but usually asymptomatic, complication following cardiac device
placement. In addition to reviewing the literature on incidence, pathogenesis and management options
for this important clinical problem, we describe two cases of symptomatic subclavian vein occlusion
following pacemaker/defibrillator placement and successful treatment with venoplasty and stenting.
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The number of pacemakers and defibrillators implanted
in the United States and worldwide continues to
increase. In 2009 alone, there were more than 1 million
pacemaker insertions or replacements and more
than 300,000 defibrillator implants. These numbers
continue to grow along with an aging population and
expanding indications for device therapy.1 Subclavian
vein stenosis/occlusion following transvenous cardiac
device placement is a known complication of the
procedure.2,3 It is an important clinical problem to
recognize, especially with the increasing numbers of
pacemaker and defibrillator implantations. Subclavian
vein stenosis can lead to symptoms such as ipsilateral
arm edema, parasthesia and pain in a minority of
patients. Acute thrombosis related to the cardiac
device is rare but most often symptomatic. Chronic
thrombosis/stenosis is more common but usually
asymptomatic.
Subclavian vein stenosis related to an intracardiac
device, even when asymptomatic, can lead to problems
with lead revision or device exchange.2,3 Variable
incidence has been reported in the literature, but up
to 50% of patients may develop at least moderate
subclavian vein stenosis, defined in most studies as
a greater than 50% luminal narrowing by contrast
venography. Even with more severe luminal narrowing
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(greater than 70%), most patients remain asymptomatic
due to venous collateral formation.4-8 Risk factors
for subclavian vein stenosis have not been well
elucidated. Various management strategies have been
employed, including anticoagulation, lead extraction,
percutaneous venoplasty with or without stenting, and
surgical bypass. However, no consensus regarding the
optimal treatment of this problem exists, and there is
limited evidence to support one approach over another.
Herein we review the literature in an effort to further
understand what questions have been answered
and areas where further study is important for the
management of this unique vascular complication. Also
provided are descriptions of two cases of symptomatic
subclavian vein occlusion associated with transvenous
pacemaker and defibrillator leads that were treated at
our institution with successful percutaneous venoplasty
and stenting.
Illustrative Case #1 (Figure 1)
A 67-year-old man with a history of idiopathic dilated
cardiomyopathy and paroxysmal atrial fibrillation
on rivaroxaban anticoagulation (with documented
compliance) underwent placement of a left-sided
biventricular implantable cardioverter defibrillator
(Viva XT, Medtronic Inc., Minneapolis, MN) one year
prior to presentation. There was no prior history of
clotting disorders or venous thromboembolism. The
procedure and immediate postoperative course were
without complications.
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Figure 1. A: Subclavian venography demonstrating

Figure 2. A: Subclavian venography demonstrating

One month prior to presentation, the patient saw his
primary care physician with a complaint of isolated,
painful left arm and hand swelling. The patient also
noticed visible venous collaterals over the left shoulder
and pectoral area. Upper extremity venous ultrasound
raised concern for significant left subclavian vein
stenosis or occlusion but was limited in its evaluation
due to the presence of existing pacemaker leads and
the left clavicle. The patient was advised to undergo
further evaluation with a venogram.

was dilated at the lead insertion site with 5 × 40-mm
and 10 × 40-mm balloons, and brisk antegrade flow
was restored. However, with the removal of the wire,
repeat angiography demonstrated reocclusion due to
recoil at the lesion site. After consultation with the
patient’s electrophysiologist, a decision was made
to proceed with stenting with the full understanding
that the implanted pacemaker leads would be trapped
behind the stent. A 12 × 60-mm stent (LifeStar®, Bard
Peripheral Vascular Inc., Tempe, AZ) was deployed and
postdilated using a 10-mm balloon, with an excellent
angiographic result.

total occlusion in the presence of a biventricular implantable cardioverter-defibrillator with collateral formation.
B: Balloon venoplasty was performed. C: Significant
recoil can be seen on postvenoplasty angiography. D:
After stenting the lesion, only minimal residual stenosis
is evident.

Left subclavian venography accessed via the left
brachial vein demonstrated a total occlusion of the left
subclavian vein near the site of entry of the pacemaker
wires. There was difficulty in crossing the lesion from
the arm with multiple catheters and wires. Femoral
venous access was obtained and an attempt was made
to cross from a retrograde approach. Ultimately, using
retrograde injections, a support catheter (QuickCross®, Spectranetics Corp., Colorado Springs, CO)
and stiff glidewire were used to successfully cross
the lesion from an antegrade approach. The lesion
Review

total occlusion in the presence of a single-chamber
pacemaker. B: Balloon venoplasty. C: Significant recoil
is shown on postvenoplasty angiography. D: After stenting the lesion, only minimal residual stenosis is evident.

Illustrative Case #2 (Figure 2)
A 79-year-old man with a history of hypertension, postsurgical revascularization coronary artery disease and
persistent atrial fibrillation on warfarin anticoagulation
underwent implantation of a single-chamber pacemaker
(Accent™, St. Jude Medical Inc., St. Paul, MN) one
year prior to presentation for tachycardia-bradycardia
syndrome. There was no history of previous venous
thromboembolism or clotting disorder, and the patient
www.aurora.org/jpcrr
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was compliant with anticoagulation. The procedure and
immediate postprocedure course were uncomplicated.
Ten months following pacemaker implantation, the
patient saw his primary care physician for isolated left
arm and hand swelling and development of dilated
venous collaterals over the left chest area. A duplex
ultrasound was ordered at that time and demonstrated
slow flow in the left subclavian vein, raising suspicion
of stenosis or occlusion of the subclavian vein. A
venogram was recommended.
Left subclavian venography accessed via the left
brachial vein demonstrated a total occlusion of the left
subclavian vein near the entry site of the pacemaker
lead. Using an angled glidewire, we were able to cross
the occlusion. Venoplasty was then performed with an
8 × 40-mm balloon with multiple inflations up to 10
atmospheres. An 8 × 40-mm noncompliant balloon
was then used up to 14 atmospheres, given significant
recoil at the lesion site after initial venoplasty. Because
of unsatisfactory flow across the lesion, a 12 × 40mm stent (LifeStent®, Bard Peripheral Vascular) was
deployed and postdilated with an 8-mm noncompliant
balloon, with an excellent angiographic result.
At 1-month follow-up, both patients had complete
resolution of the arm swelling, and the subcutaneous
venous collaterals had completely disappeared.
Pathophysiology
Venous thrombosis and stenosis were reported in the
literature shortly after the first transvenous pacemakers
were implanted. Early and late venous thrombosis
has been described.5,6 Late thrombosis is often
asymptomatic, the result of chronic fibrosis around
the device leads that enables collaterals to form.
Acute venous thrombosis is less common and often
symptomatic. Most of the modern histopathologic data
has focused on the complex inflammatory and fibrotic
changes that occur at the endocardial lead interface.
Autopsy studies have identified similar inflammatory
and fibrotic changes at the insertion site of the device
leads in the vein.9,10 Dense fibrotic adhesions are
routinely encountered when lead removal is necessary
and have formed the basis for the development of
excimer laser lead extraction.11 This fibrosis can occur
more frequently at characteristic anatomic sites like
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the lead insertion point, venous bifurcation sites and
the costoclavicular space. It is not well characterized
why particular anatomic sites are more prone to
stenosis, but the cause is likely multifactorial and
related to endothelial injury from insertion as well as
repetitive mechanical trauma at bifurcation sites or
where bony compression may occur. Two studies have
suggested that temporary pacemaker insertion prior
to permanent implant and prior pacemaker insertion
before defibrillator placement were risk factors
associated with stenosis, presumably due to repetitive
vessel trauma.7,12
Epidemiology
The incidence of subclavian vein stenosis after device
implantation varies widely in the literature, ranging
from 30% to 50%.4-8,12,13 Some of this variation
depends on the modality used to diagnose the
problem, i.e. ultrasound versus contrast venography.
Other reasons for the variation are likely diverse
study populations that vary considerably in size, both
retrospective and prospective data acquisition and
nonstandard definitions of significant stenosis.
Multiple studies in which routine postimplant
venography was performed have demonstrated
significant stenosis rates. Many studies have defined
the degree of stenosis as mild (<50%), moderate
(50–70%) and severe (>70%). Antonelli et al.5
performed consecutive venography on 40 patients
and found significant venous stenosis in 23% at a
mean postprocedure follow-up of 4 months. Studies
with longer follow-up have reported rates as high as
50%. Da Costa and colleagues7 prospectively studied
venography at 6 months postimplant in 202 patients.
Greater than moderate stenosis was identified in 51%
of patients. Most of the patients in these studies were
asymptomatic, thought to be secondary to collateral
venous circulation that develops as the stenosis
gradually worsens. The incidence of symptomatic
subclavian vein stenosis in patients with cardiac
devices is estimated at 1–5%. However, this may be an
underreported clinical problem.
Risk factors for the development of subclavian
vein stenosis have been described but are not well
characterized. In Da Costa et al.’s study of both
symptomatic and asymptomatic patients, low ejection
fraction and a prior temporary pacemaker conveyed
Review

increased risk. There are conflicting data on whether
the number of leads present conveys greater risk. Other
studies have investigated but found no link in a variety
of patient- and device-specific factors. These include
age, sex, pacemaker or defibrillator device, time
from lead implant, lead type or material (silicone or
polyurethane) and entry site, among others.7,13
Clinical Characteristics and Diagnosis
Symptomatic patients with chronic lead-related
subclavian vein stenosis/occlusion often present more
than one month after device implantation with painful
arm swelling that may be associated with cyanosis and
visible venous collaterals over the ipsilateral chest and
upper extremity. Rarely, pulmonary embolism can be
a presenting symptom as reported in Da Costa et al.’s
prospective study.7 The majority of patients remain
asymptomatic due to venous collateral formation.
Symptoms may develop due to inadequate collaterals
or their acute obstruction, an acute thrombotic event
on an existing moderate venous stenosis in which
collaterals have not formed, or the presence of an
ipsilateral arteriovenous fistula in dialysis patients.14
Diagnosis may be apparent based on history and physical
exam alone. Often, a venous duplex ultrasound will
identify a high-grade stenosis or occlusion.15 Computed
tomography is an additional noninvasive option when
ultrasound is unavailable or inadequate.16 Definitive
diagnosis is made with contrast venography.2,12
Management
The optimal management strategy for the treatment
of patients with subclavian vein stenosis related to a
transvenous lead has not been systematically studied.
Most of the literature has focused on management
options for asymptomatic patients with venous stenosis
who need an additional lead or lead revision and in
whom the diagnosis is made incidentally.17-22 Options
for management of these patients include contralateral
access, lead extraction with reimplantation or
epicardial lead placement. Surgical approaches for
bypass or reconstruction exist but are rarely used in
the modern era.23 An alternative option, percutaneous
venoplasty, is being increasingly utilized as a safe
and effective method to preserve ipsilateral access
even in the setting of chronic occlusion. Worley and
colleagues24 reported successful venoplasty in 371
Review

of 373 consecutive patients (over an 11-year period)
who were found to have significant subclavian stenosis
while undergoing lead revision or upgrade.
The optimal management strategy of the symptomatic
patient with subclavian stenosis in which the existing
lead is functioning normally is not known. Spittell et
al.25 reported early success with balloon venoplasty
in the treatment of two patients with symptomatic
venous stenosis. Conservative options include
watchful waiting for collateral vessels to develop.
Anticoagulation and thrombolytic therapy also have
been utilized, but they are unlikely to be effective for
the chronic fibrotic lesions that often exist in these
patients.23 For the persistent symptomatic patient,
device extraction can be considered, but this comes
with an approximately 1–2% risk of significant
morbidity and mortality, including tamponade, valve
injury and hemothorax.11 Venoplasty with or without
stenting is an alternative approach that enables the
device and leads to stay in place, avoiding the risks of
lead extraction as well as preserving ipsilateral access.
In Worley et al.’s large, retrospective, single-center
review, no procedural complications were noted in 373
venoplasty procedures.24
Many reports in the literature describe the successful
treatment of symptomatic patients with superior vena
cava stenosis due to transvenous leads.26-30 Riley et al.23
performed a pooled analysis of 104 patients treated
for lead-associated superior vena cava syndrome over
a period of 39 years. The treatment options included
anticoagulation (n=29 patients), thrombolysis (n=11),
venoplasty (n=16), surgery (n=23) and stenting
(n=25). Stenting was the superior modality, with 5%
recurrence over a median of 9.5 months. Surgery had a
12% recurrence rate, venoplasty 23%, anticoagulation
21% and thrombolysis 33%. Complication rates were
not reported.
Kalman et al.31 reported their single-center experience
with a small heterogeneous group of patients with
symptomatic venous stenosis treated with a variety
of interventional techniques, including directed
thrombolysis, venoplasty and stenting as a bailout option. Of the patients in their cohort, 15%
had a pacemaker lead and 15% received a stent.
They reported a 70% 2-year patency rate for the
www.aurora.org/jpcrr

115

entire group, with no complications noted from the
stenting technique. The low rate of stent use is in
line with the Heart Rhythm Society expert consensus
recommendation to avoid stenting in patients with
symptomatic pacemaker-related subclavian stenosis.32
There is concern that stenting can damage device leads
and lead to pacemaker malfunction, but this has been
reported rarely in the literature.33

relief of symptoms in two patients. It is important
to know it remains an option for the select group of
patients with symptomatic subclavian vein stenosis
related to an implanted cardiac device.

Conclusions
Cardiac device-related subclavian vein stenosis is a
common problem that most often remains clinically
silent. The two patients presented here were both
symptomatic, with venography demonstrating
subclavian vein occlusion. Both were approximately
one year removed from device implant at the onset of
symptoms, a common time frame for this occurrence.
One had a single-lead pacemaker and the other a
biventricular device. It may be that lead burden is only
one of many contributing factors in this complication.
Interestingly, both patients were on chronic therapeutic
anticoagulation for the treatment of atrial fibrillation.
The pathophysiology of lead-related venous stenosis
may be unrelated to any acute thrombotic event but
more likely is a chronic inflammatory and fibrotic
reaction driven by endothelial injury and mechanical
trauma. No prospective data exist on the benefit of
anticoagulation therapy to prevent venous stenosis
surrounding cardiac device implantation; this is an
area in need of further study.

• This complication is occurring more frequently as
the overall use of implanted devices increases.

Both of our patients were treated with venoplasty and
stenting due to unsatisfactory results with balloon
inflation alone. The long-term outcomes of this
approach are not known, and limited data exist for the
use of this approach in the subclavian vein. It has been
shown to be a reasonable strategy with good shortterm outcomes when used in the superior vena cava
with retention of device leads.22 The dense fibrosis
of these lesions, causing significant recoil, can lead
to venoplasty failure. Aggressive balloon inflation
in this setting may lead to perforation. Stenting is a
safe alternative that improves procedural success
and ipsilateral access. The obvious limitation of this
technique is a lack of both short- and long-term data
from a larger patient population specifically targeting
subclavian vein stenosis. We have shown here that it is
a safe and effective approach for the nearly immediate
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JPCRR • Volume 2, Issue 3 • Summer 2015

Patient-Friendly Recap
• Blockage of blood flow in the subclavian vein is
common following placement of a cardiac device.

• A combination of venoplasty and stenting may
effectively relieve painful symptoms that afflict
some patients.
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